NCT03102489View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 22, 2017

Primary Completion Date

June 21, 2017

Study Completion Date

September 19, 2017

Conditions
Hypoactive Sexual Desire Disorder(HSDD)
Interventions
DRUG

BP101

Nasal spray

DRUG

Placebo

Nasal spray

Trial Locations (1)

Unknown

Research center Eco-Safety LLC, Saint Petersburg

All Listed Sponsors
lead

Ivix LLX

INDUSTRY

NCT03102489 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy Volunteers | Biotech Hunter | Biotech Hunter